Plain-English translation of NCT05365581 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called that works by connecting to a specific protein on cancer cells and signaling your immune system to attack them. The medication may be given by itself or combined with standard cancer treatments. Researchers are studying how safe the medication is, what side effects it causes, and what dose works best.
Stomach, gastroesophageal junction, and pancreatic cancers are serious diseases that are often diagnosed at advanced stages when surgery isn't possible. This medication is being studied because it targets a protein called CLDN18.2 that appears on many of these cancer cells, offering a potentially new way to help your immune system fight the disease.
You likely qualify if…
You likely don't qualify if…
You will receive the medication either alone or combined with standard cancer treatments, depending on which group you are assigned to. The study begins with a dose-escalation phase where researchers carefully increase the dose to find the safest and most effective level, followed by an expansion phase where more participants receive the chosen dose. You will have regular clinic visits for blood tests, imaging scans, and medical check-ups to monitor how you are responding and watch for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.